Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wilcox, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilcox, M. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 358-359
© 2001 The British Society for Antimicrobial Chemotherapy

Correspondence

Clarithromycin and risk of Clostridium difficile-associated diarrhoea

Mark H. Wilcox

Department of Microbiology, University of Leeds and The General Infirmary, Leeds LS2 9JT, UK

Sir,

Guyot and colleagues1 reported a retrospective analysis of antibiotic and other potential risk factors in Clostridium difficile-associated diarrhoea in elderly in-patients. They claimed that clarithromycin was a significant risk factor for C. difficile-associated diarrhoea, but there are important caveats to their report. Most important was their choice of control patients. Rather than comparing risks in cases with those in asymptomatic controls, the authors . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. H. Wilcox, J. Freeman, W. Fawley, S. MacKinlay, A. Brown, K. Donaldson, and O. Corrado
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea
J. Antimicrob. Chemother., July 1, 2004; 54(1): 168 - 172.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Thomas, M. Stevenson, and T. V. Riley
Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review
J. Antimicrob. Chemother., June 1, 2003; 51(6): 1339 - 1350.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Guyot and S. P. Barrett
What is an appropriate control group to identify risk factors for Clostridium difficile-associated diarrhoea?
J. Antimicrob. Chemother., November 1, 2001; 48(5): 747 - 748.
[Full Text] [PDF]